Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs)
cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed …

Aims The first aim was to critically evaluate the extent to which familial hypercholesterolaemia
(FH) is underdiagnosed and undertreated. The second aim was to provide guidance for …

Aims Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition
characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (…

Aims The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a
cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp(a), on …

Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary heart
disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and treated …

Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic
abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically …

This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement
updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and …

… Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps
OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK …

Aims To critically evaluate the clinical implications of the use of non-fasting rather than
fasting lipid profiles and to provide guidance for the laboratory reporting of abnormal non-fasting …

Objectives : This study sought to evaluate the efficacy and safety of subcutaneous evolocumab
compared with oral ezetimibe in hypercholesterolemic patients who are unable to tolerate …